Biolex Therapeutics Announces Recruitment Of Three Key Management Team Additions To Accelerate Commercialization Of Lead Programs
Published: Nov 16, 2005
PITTSBORO, N.C., Nov. 16 /PRNewswire/ -- Biolex Therapeutics, a protein therapeutics company, announced today three new additions to its management team. Each of these pharmaceutical executives brings a proven track record in the development and commercialization of therapeutic proteins and complements the experienced management team already in place. These additions will help Biolex accelerate its own clinical-stage development programs as well as the programs of its strategic partners.
Mr. Glen Williams has been appointed Senior Vice President, Operations and will be responsible for Biolex' existing GMP operations as well as the design and implementation of the Company's next-generation GMP production facilities. Mr. Williams brings to Biolex over 20 years of professional experience in biopharmaceutical manufacturing. In addition to overseeing major GMP biomanufacturing operations, he has an extensive background in engineering operations, including the design, construction, startup and licensing of new biopharmaceutical production facilities. Mr. Williams was previously the Vice President of Manufacturing and General Manager for Biogen Idec's Research Triangle Park (NC) facilities, where he was responsible for site-wide manufacturing operations for new and marketed recombinant therapeutic proteins. Mr. Williams received his M.B.A. from Central Michigan University and his B.S. in Mechanical Engineering from The Ohio State University.
Dr. John Elliott Humphries has been appointed Vice President, Development and will lead the clinical development of Biolex' therapeutic protein candidates. Dr. Humphries has over 18 years of academic and pharmaceutical industry experience with a strong focus on hematology. Prior to joining Biolex, Dr. Humphries served in a number of senior level clinical development positions in the Biologics Division of Bayer HealthCare, LLC. Most recently at Bayer, he held the position of Director, Global Clinical Strategy for several therapeutic proteins targeting congenital deficiency, hematology, cardiology and vascular illnesses. Prior to beginning his career in drug development, Dr. Humphries held various academic appointments at the University of Virginia School of Medicine. Dr. Humphries received his A.B. in German and Biology from Middlebury College in Vermont, and his M.D. from Johns Hopkins School of Medicine.
Ms. Dee Parson Grange has been appointed Vice President, Business Development and will be responsible for evaluating new Biolex protein opportunities, as well as ensuring current products in the pipeline achieve market value. Ms. Grange brings to Biolex 20 years of broad-based global biopharmaceutical experience. Ms. Grange joins Biolex from Bayer HealthCare, LLC, where she held various strategic and business operational positions for both pharmaceutical and biological products, including the world-wide development and marketing of nine therapeutic proteins. She received her B.S. in Biology from Graceland University and her M.B.A. from Duke University.
"In 2005 we have announced a number of major milestones including our ground-breaking strategic alliance with Centocor/Johnson & Johnson and the advancement of two proteins produced in our LEX System(TM) into clinical trials," said Jan Turek, President and CEO. "The additions of Glen, John and Dee to our management team further increase our capabilities to accelerate the development and commercialization of hard-to-make proteins and monoclonal antibodies both in our Biolex pipeline and on behalf of our partners. We anticipate that these recent additions will make important contributions to the continued success of Biolex."
About Biolex Therapeutics
Biolex Therapeutics applies its unique drug development capabilities and expertise to commercialize complex proteins and monoclonal antibodies that until now have been impossible or very expensive to develop through traditional means. Biolex' patented LEX System(TM) uses Lemna as a transgenic host in its GMP biopharmaceutical manufacturing facility to produce therapeutic proteins to support its own development programs as well as the programs of its strategic partners. The company is advancing a proprietary pipeline of product candidates, including its lead program Locteron(TM) under joint development with OctoPlus. Biolex has a multi-protein strategic alliance with Centocor and collaborations with other pharmaceutical/biotech companies including Medarex and Kringle Pharma. Biolex is a venture-capital backed company located in the Research Triangle region of North Carolina, United States. For additional information, please visit Biolex' web site at www.biolex.com.
Michelle Linn, Linnden Communications, 508-419-1555, firstname.lastname@example.org.Biolex Therapeutics
CONTACT: Michelle Linn of Linnden Communications, +1-508-419-1555, email@example.com, for Biolex Therapeutics
Web site: http://www.biolex.com/